Careers  |  Sign In  |  Register

AML Patient Case: 82-Year-Old Patient Presents With Pancytopenia (Part 2)

Part 2 – Case Discussion

Daniel A. Pollyea, MD, MS, presents the case of patient “L.L.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).

Click here to learn more by viewing Part 3 – Case Discussion & Wrap-up.

Disclosures:

Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie

Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz

Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas

References:

  1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020. Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
  2. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140. PMID: 31841594; PMCID: PMC7019193.
  3. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16. PMID: 30555165; PMCID: PMC6365492.
  4. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18. PMID: 31628431.

Faculty

Brian A. Jonas, MD, PhD, FACP
Brian A. Jonas, MD, PhD, FACP

Associate Professor of Medicine

Chair, Hematologic Malignancies Disease Team Committee

Division of Hematology and Oncology

University of California Davis School of Medicine

Sacramento, CA

Gabriel N. Mannis, MD
Gabriel N. Mannis, MD

Assistant Professor of Medicine

Division of Hematology

Stanford Cancer Institute

Stanford University

Stanford, CA

Daniel A. Pollyea, MD, MS
Daniel A. Pollyea, MD, MS

Associate Professor of Medicine

Clinical Director of Leukemia Services

Robert H. Allen MD Chair in Hematology Research

Division of Hematology

University of Colorado School of Medicine

Aurora, CO